ONX-0914
CAS No. : 960374-59-8
(Synonyms: PR-957)
| Size | Price | Stock |
|---|---|---|
| 5mg | $150 | In-stock |
| 10mg | $240 | In-stock |
| 25mg | $480 | In-stock |
| 50mg | $750 | In-stock |
| 100mg | $1180 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-13207 |
| M.Wt: | 580.67 |
| Formula: | C31H40N4O7 |
| Purity: | >98 % |
| Solubility: | DMSO : ≥ 35 mg/mL |
ONX-0914 (PR-957) is a selective inhibitor of low-molecular mass polypeptide-7 (LMP7), the chymotrypsin-like subunit of the immunoproteasome. ONX-0914 blocks cytokine production and attenuates progression of experimental arthritis. ONX-0914 is a noncompetitive irreversible inhibitor of the mycobacterial proteasome (Ki=5.2 μM). ONX-0914 reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1[1][2][3].
IC50 & Target: IC50: ~10 nM (LMP7)[1].
In Vitro: ONX-0914 inhibits LMP7-specific antigen presentation. ONX-0914 blocks cytokine productionby mouse splenocytes and blocks T celldifferentiation[1].
In Vivo: ONX-0914 (2-10 mg/kg; i.v,; on days 4, 6 and 8) meliorates disease in mouse arthritis[1].
ONX-0914 (2, 6 and 10 mg per kg body weight on days 25, 27, 29, 31 and 33; i.v.) treatment also induced a rapid therapeutic response in the T and B cell–dependent CIA (collagen-induced arthritis) model[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- ONX-0914
- Cat. No.:
- HY-13207
- Quantity:
Your information is safe with us.